Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib 160 mg First-line Therapy in EGFR/TP53 Co-mutant Advanced NSCLC
ChiCTR2600124298Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Started May 2026; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600124298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124298.